Douglas Wilson

USPTO Granted Patents = 30 (Patent Applications = 15)

CIPO Patents = 5 (Patent Applications = 4)

EPO Patents = 6 (Patent Applications = 12)

Average Co-Inventor Count = 5.2

ph-index = 12

Forward Citations = 425(Granted Patents)

Location History:

Mercer Island, WA (US) (2011 - 2020)
Cambridge, MA (US) (2023)
Ayer, MA (US) (2009 - 2024)

Company Filing History:

19 out of 60

Blueprint Medicines Corporation

Years Active: 2009-2025

Loading Chart...

30 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12486041 - Computation of aircraft airspeed by inclusion of static air temperature (2025-12-02),

2. 12448379 - Wild type kit inhibitors (2025-10-21),

3. 12172983 - EGFR inhibitors (2024-12-24),

4. 11970498 - CDK2 inhibitors (2024-04-30),

5. 11932648 - CDK2 inhibitors (2024-03-19),

6. 11827642 - Compositions useful for treating disorders related to KIT (2023-11-28),

7. 11718602 - EGFR inhibitors (2023-08-08),

8. 11634422 - Inhibitors of activin receptor-like kinase (2023-04-25),

9. 11279688 - Inhibitors of RET (2022-03-22),

10. 10768201 - System for estimating airspeed of an aircraft based on a drag model (2020-09-08),

11. 10759544 - Methods and systems for controlling thrust produced by a plurality of engines on an aircraft for assisting with certain flight conditions (2020-09-01),

12. 10584114 - Inhibitors of RET (2020-03-10),

13. 10233186 - Inhibitors of activin receptor-like kinase (2019-03-19),

14. 10227329 - Compounds useful for treating disorders related to RET (2019-03-12),

15. 10030005 - Inhibitors of RET (2018-07-24),

Title: Douglas Wilson: Innovator in Cancer Treatment

Introduction: Douglas Wilson, based in Ayer, MA, has made significant contributions to the field of oncology through his innovative work in developing targeted therapies. With a remarkable portfolio that includes 20 patents, he is recognized for his efforts in advancing treatments for cancer.

Latest Patents: Among his latest patents, Douglas Wilson has developed EGFR inhibitors, which encompass compounds aimed at treating various cancers through specific pathways. Additionally, he has worked on CDK2 inhibitors, providing further options for therapeutic intervention in cancer treatment. These compounds are represented by structural formulas that denote their potential utility as effective medications.

Career Highlights: Throughout his career, Douglas has worked with notable companies such as Blueprint Medicines Corporation and Wyeth. His experience in these organizations has allowed him to engage in cutting-edge research and development, leading to his impressive patent portfolio.

Collaborations: Douglas has also collaborated with distinguished coworkers, including Joseph L. Kim and Kevin J. Wilson. These partnerships have fostered innovative research and have contributed to the successful development of new cancer therapies.

Conclusion: Douglas Wilson's work exemplifies the spirit of innovation in pharmaceuticals, particularly in cancer treatment. His patents not only showcase his creativity as an inventor but also reflect the collaborative efforts that drive significant advancements in healthcare. Douglas continues to inspire aspiring inventors and researchers in the field of oncology.

This text is generated by artificial intelligence and may not be accurate.